| Literature DB >> 23272110 |
Samuel Rhedin1, Johan Hamrin, Pontus Naucler, Rutger Bennet, Maria Rotzén-Östlund, Anna Färnert, Margareta Eriksson.
Abstract
BACKGROUND: The swine-origin influenza A(H1N1)pdm09 pandemic of 2009 had a slower spread in Europe than expected. The human rhinovirus (HRV) has been suggested to have delayed the pandemic through viral interference. The importance of co-infections over time during the pandemic and in terms of severity of the disease needs to be assessed.Entities:
Mesh:
Year: 2012 PMID: 23272110 PMCID: PMC3522717 DOI: 10.1371/journal.pone.0051491
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Viral co-detection among PCR-positive samples.
| Detected virus, n (%) | ||||||||||||
| H1N1 | HAdV | HBoV | HCoV | HEV | HMPV | HRV | RSV | PIV1 | PIV2 | PIV3 | ||
| Positive samples | 83 (16.5) | 29 (5.8) | 29 (5.8) | 17 (3.4) | 13 (2.6) | 2 (0.4) | 141 (28.1) | 12 (2.4) | 22 (4.4) | 9 (1.8) | 2 (0.4) | |
| Single infections | 71 (85.5) | 18 (62.1) | 11 (37.9) | 6 (35.3) | 12 (92.3) | 1 (50.0) | 111 (78.7) | 11 (91.7) | 15 (68.2) | 8 (88.9) | 1 (50.0) | |
| Co-infections | 12 (14.5) | 11 (37.9) | 18 (62.1) | 11 (64.7) | 1 (7.7) | 1 (50.0) | 30 (21.3) | 1 (8.3) | 7 (31.8) | 1 (11.1) | 1 (50.0) | |
| H1N1 | – | 3 (10.3) | 4 (13.8) | 1 (5.9) | 1 (50.0) | 5 (3.5) | 1 (4.5) | |||||
| HAdV | 3 (3.6) | – | 1 (5.9) | 8 (5.7) | 1 (4.5) | |||||||
| HBoV | 4 (4.8) | – | 3 (17.6) | 1 (7.7) | 1 (50.0) | 9 (6.4) | 1 (4.5) | 1 (11.1) | ||||
| HCoV | 1 (1.2) | 1 (3.4) | 3 (10.3) | – | 6 (4.3) | 1 (4.5) | 1 (50.0) | |||||
| HEV | 1 (3.4) | – | ||||||||||
| HMPV | 1 (1.2) | 1 (3.4) | – | 1 (0.7) | ||||||||
| HRV | 5 (6.0) | 8 (27.6) | 9 (31.0) | 6 (35.3) | 1 (50.0) | – | 1 (8.3) | 3 (13.6) | 1 (11.1) | |||
| RSV | 1 (0.7) | – | ||||||||||
| PIV1 | 1 (1.2) | 1 (3.4) | 1 (3.4) | 1 (5.9) | 3 (2.1) | – | ||||||
| PIV2 | 1 (3.4) | 1 (0.7) | – | |||||||||
| PIV3 | 1 (5.9) | – | ||||||||||
Number in brackets representing percentage of total children (n = 502).
Triple and quadruple infections counted as multiple double infections.
Figure 1Prevalence over time.
Total number of detected viruses among children with influenza-like illness at Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm during the influenza A(H1N1)pdm09 pandemic. Included is also the number of PCR-negative children (neg, n = 193) as well as total number of sampled children (n = 502).
Figure 2Co-infections over time.
Number of children with co-infections over time in (a) all children and (b) H1N1-positive children. H1N1-positive co-infected children divided into co-infection with HRV (H1N1/HRV) and co-infection with other viruses (H1N1/other).
Distribution of virus in H1N1-positive and H1N1-negative samples.
| Detected virus | Totaln | H1N1-negativen (%) | H1N1-positiven (%) | p-value |
| HAdV | 29 | 26 (11.5) | 3 (3.6) |
|
| HBoV | 29 | 25 (11.1) | 4 (4.8) | 0.12 |
| HCoV | 17 | 16 (7.1) | 1 (1.2) |
|
| HEV | 13 | 13 (5.8) | 0 (0.0) |
|
| HMPV | 2 | 1 (0.4) | 1 (1.2) | 0.47 |
| HRV | 141 | 136 (60.2) | 5 (6.0) |
|
| RSV | 12 | 12 (5.3) | 0 (0.0) |
|
| PIV1 | 22 | 21 (9.3) | 1 (1.2) |
|
| PIV2 | 9 | 9 (4.0) | 0 (0.0) | 0.12 |
| PIV3 | 2 | 2 (0.9) | 0 (0.0) | 1.00 |
| Co-infections | 33 (14.6) | 12 (14.5) | 0.26 | |
| Single infections | 193 (85.4) | 71 (85.5) | ||
| No. of positive samples | 226 | 83 | ||
| Total no. of samples | 419 | 83 |
Figure 3Co-infections and age.
Comparison of number of co-infections according to age between children under 1 year (<1), children 1–6 years (1–6) and children over six years (>6) in (a) all children and (b) H1N1-positive children. H1N1-positive co-infected children divided into co-infection with HRV (H1N1/HRV) and co-infection with other viruses (H1N1/other).
Severity of disease and underlying conditions in children admitted with influenza-like illness.
| H1N1 single infection (n = 71)median/n (%) | H1N1 coinfection (n = 12)median/n (%) | p-value | |||
| Age | 3.5 | 2.7 | 0.25 | ||
| Male sex | 41 (57.7) | 8 (66.7) | 0.75 | ||
| UNDERLYING DISEASE | |||||
| Healthy | 40 (56.3) | 6 (50.0) | 0.68 | ||
| Asthma | 11 (15.5) | 0 (0.0) | 0.35 | ||
| Neuromuscular disease | 6 (8.5) | 3 (25.0) | 0.12 | ||
| Immunosuppression | 5 (7.0) | 1 (8.3) | 1.00 | ||
| Prematurity/VOC/chronic respiratory disease | 4 (5.6) | 2 (16.7) | 0.21 | ||
| Other | 5 (7.0) | 0 (0.0) | 1.00 | ||
| SEVERITY OF DISEASE | |||||
| Uncomplicated | 34 (47.9) | 3 (25.0) | 0.21 | ||
| Respiratory problems | 14 (19.7) | 3 (25.0) | 0.70 | ||
| Bacterial infections | 8 (11.3) | 4 (33.3) | 0.07 | ||
| Seizures | 4 (5.6) | 1 (8.3) | 0.55 | ||
| Other | 9 (12.7) | 1 (8.3) | 1.00 | ||
| Intensive care | 7 (9.9) | 2 (16.7) | 0.61 | ||
| Days admitted (range) | 2 (1–23) | 3 (1–12) | 0.45 | ||
| Deaths | 2 (2.8) | 0 (0.0) | 1.00 | ||
Renal, metabolic and gastrointestinal diseases.
Including gastroenteritis, ileus, metabolic acidosis, myocarditis, renal failure, encephalitis, viral meningitis and myositis.